Arrowhead Pharmaceuticals Net Tangible Assets

Arrowhead Pharmaceuticals (ARWR) currently reports a net tangible assets of $470M as of June 2026. That compares with $520M in the prior-year period — down 9.9% year over year. Use the charts on this page to explore Arrowhead Pharmaceuticals's net tangible assets history and peer comparisons.

Arrowhead Pharmaceuticals's net tangible assets decreased from $520M to $470M — a 9.9% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Arrowhead Pharmaceuticals reported $470M in net tangible assets as of June 2026. That compares with $520M in the prior-year period — down 9.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net tangible assets of $470M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Arrowhead Pharmaceuticals, and consider following ARWR for alerts when major investors trade the stock.

Arrowhead Pharmaceuticals is classified in the Healthcare sector. On net tangible assets, it currently shows $470M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARWR with unrelated industries.